Cabaletta Bio, Inc. (CABA)
NASDAQ:CABA
Want to see CABA full AI Analyst Report?
Top Page
Cabaletta Bio
(NASDAQ:CABA)
Select Model
Select Model
Rating:50Neutral
Price Target:
$3.50
▲(1.74% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and heavy cash burn). Offsetting that, technicals show improving trend/momentum and corporate updates include positive early clinical data plus a major financing that improves runway, but valuation remains constrained by ongoing unprofitability.
Positive Factors
Clinical Efficacy Signals
Robust, durable clinical responses and tolerability in the lowest-dose, no‑preconditioning cohort materially de-risk the rese-cel program. Sustained drug‑free remissions in some patients strengthen the case for registrational development and support expansion into multiple autoimmune indications over the next 2–3 years.
Negative Factors
No Revenue / Widening Losses
The company remains clinical-stage with zero product revenue and rapidly expanding losses, meaning core value depends solely on future trial success and approvals. Persistent unprofitability creates structural reliance on capital markets and increases dilution risk as programs move through costly late‑stage trials.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Efficacy Signals
Robust, durable clinical responses and tolerability in the lowest-dose, no‑preconditioning cohort materially de-risk the rese-cel program. Sustained drug‑free remissions in some patients strengthen the case for registrational development and support expansion into multiple autoimmune indications over the next 2–3 years.
Read all positive factors
Cabaletta Bio (CABA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$560.91M
Dividend YieldN/A
Average Volume (3M)3.89M
Price to Earnings (P/E)―
Beta (1Y)4.17
Revenue GrowthN/A
EPS Growth22.16%
CountryUS
Employees161
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.97
Shares Outstanding163,054,800
10 Day Avg. Volume4,522,481
30 Day Avg. Volume3,894,979
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.54
Forecast
1Y Price Target
$13.94Price Target Upside305.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.59
Revenue Forecast (FY)N/A
Cabaletta Bio Business Overview & Revenue Model
Company Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody r...
How the Company Makes Money
As a clinical-stage biotechnology company, Cabaletta Bio does not have product sales and therefore does not generate recurring commercial revenue from approved therapies. The company has historically funded operations primarily through financing a...
Cabaletta Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -171.58M | -164.21M | -113.41M | -66.25M | -52.96M | -45.58M |
| Net Income | -175.43M | -167.86M | -115.86M | -67.67M | -52.98M | -46.29M |
Balance Sheet | ||||||
| Total Assets | 148.15M | 165.08M | 185.05M | 253.65M | 116.97M | 126.34M |
| Cash, Cash Equivalents and Short-Term Investments | 116.64M | 133.60M | 163.96M | 241.25M | 106.55M | 122.22M |
| Total Debt | 26.45M | 27.10M | 15.60M | 5.02M | 5.14M | 0.00 |
| Total Liabilities | 44.84M | 53.03M | 32.71M | 17.45M | 12.45M | 8.38M |
| Stockholders Equity | 103.31M | 112.05M | 152.34M | 236.20M | 104.52M | 117.96M |
Cash Flow | ||||||
| Free Cash Flow | -143.28M | -132.31M | -90.43M | -54.24M | -48.83M | -35.27M |
| Operating Cash Flow | -142.84M | -131.08M | -88.22M | -53.55M | -46.38M | -34.11M |
| Investing Cash Flow | 1.48M | -50.27M | 47.29M | -22.45M | -27.22M | 6.00M |
| Financing Cash Flow | 126.17M | 100.35M | 11.68M | 187.63M | 32.98M | 48.90M |
Cabaletta Bio Technical Analysis
Positive
3.44
Price Trends
3.19
Positive
2.95
Positive
2.58
Positive
Market Momentum
0.09
Positive
57.07
Neutral
36.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CABA, the sentiment is Positive. The current price of 3.44 is above the 20-day moving average (MA) of 3.43, above the 50-day MA of 3.19, and above the 200-day MA of 2.58, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 57.07 is Neutral, neither overbought nor oversold. The STOCH value of 36.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CABA.
Cabaletta Bio Risk Analysis
Cabaletta Bio disclosed 86 risk factors in its most recent earnings report. Cabaletta Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cabaletta Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $206.29M | -3.37 | -36.37% | ― | -100.00% | -1056.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $560.91M | -1.73 | -131.58% | ― | ― | 22.16% | |
49 Neutral | $335.31M | -2.34 | -57.01% | ― | ― | -28.75% | |
48 Neutral | $231.14M | -1.17 | -67.65% | ― | 74.84% | 99.51% | |
46 Neutral | $234.48M | -3.32 | -51.22% | ― | -96.67% | -559.52% | |
45 Neutral | $198.36M | -1.82 | -100.13% | ― | 12.96% | 12.51% |
* Healthcare Sector Average
CABA
Cabaletta Bio
3.69
1.91
107.30%
TNXP
Tonix Pharma
14.00
-12.40
-46.97%
BDTX
Black Diamond Therapeutics
3.55
1.49
72.33%
AVIR
Atea Pharmaceuticals
4.24
1.39
48.77%
CRBU
Caribou Biosciences
1.99
0.89
80.91%
TRDA
Entrada Therapeutics Inc
6.31
-1.31
-17.19%
Cabaletta Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cabaletta Bio Reports Encouraging RESET-PV Trial Data
Positive
May 14, 2026
On May 14, 2026, Cabaletta Bio reported new clinical and translational data from the lowest-dose, preconditioning-free cohort of its RESET-PV trial in pemphigus vulgaris, showing that rese-cel was generally well tolerated and produced clinically m...
Business Operations and StrategyPrivate Placements and Financing
Cabaletta Bio Announces $150 Million Equity Offering
Positive
May 4, 2026
On May 4, 2026, Cabaletta Bio priced an underwritten registered direct offering of 51,725,000 shares of common stock at $2.90 per share, raising expected gross proceeds of about $150 million and estimated net proceeds of roughly $141 million. The ...
Business Operations and Strategy
Cabaletta Bio reports promising RESET-PV and RESET-SLE data
Positive
May 4, 2026
On May 14, 2026, Cabaletta Bio planned to present new clinical and translational data from four refractory pemphigus vulgaris patients treated with the lowest dose of rese-cel without preconditioning in its RESET-PV trial, with follow-up ranging f...
Business Operations and StrategyProduct-Related Announcements
Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans
Positive
Apr 20, 2026
On April 20, 2026, Cabaletta Bio posted an updated corporate presentation outlining progress and plans for rese-cel, its CD19-CAR T cell therapy for autoimmune diseases, on the Investors Media section of its website. The presentation highlights a...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Cabaletta Bio Updates Rese-cel Programs and Financial Outlook
Positive
Mar 23, 2026
On March 23, 2026, Cabaletta Bio reported fourth-quarter and full-year 2025 results and outlined progress on rese-cel, its lead CAR T therapy for autoimmune diseases. The company said its RESET-Myositis registrational cohort is enrolling 17 dermat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.